Cytotoxic compounds in the treatment of castration-resistant prostate cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 1040-1045

  Lee, Patrick ^a   Aragon Ching, Jeanny B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Docetaxel; Epothilones; Microtubule targeting agents; Platinum; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERIBULIN; ESTRAMUSTINE; FLUOROURACIL; GEMCITABINE; IXABEPILONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PICOPLATIN; PLACEBO; PLATINUM COMPLEX; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SATRAPLATIN; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; WARFARIN; XRP 6258; CYTOTOXIN;

ALOPECIA; ANALGESIA; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CASTRATION; CELL CYCLE ARREST; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; DEPOLYMERIZATION; DNA ALKYLATION; DNA REPLICATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; LOW DRUG DOSE; METASTASIS POTENTIAL; MISMATCH REPAIR; MITOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POLYMERIZATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; CHEMISTRY; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYTOTOXINS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 73349095379     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789734991     Document Type: Review

References (79)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59(4), 225-249.
2. Tannock, I.F.; Osoba, D.; Stockler, M.R.; Ernst, D.S.; Neville, A.J.; Moore, M.J.; Armitage, G.R.; Wilson, J.J.; Venner, P.M.; Coppin, C.M.; Murphy, K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 1996, 14(6), 1756-1764.
3. Kantoff, P.W.; Halabi, S.; Conaway, M.; Picus, J.; Kirshner, J.; Hars, V.; Trump, D.; Winer, E.P.; Vogelzang, N.J. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol., 1999, 17(8), 2506-2513.
4. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A.; Eisenberger, M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351(15), 1502-1512.
5. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N., Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med., 2004, 351(15), 1513-1520.
6. Berthold, D.R.; Pond, G.R.; de Wit, R.; Eisenberger, M.; Tannock, I.F. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann. Oncol., 2008, 19(10), 1749-1753.
7. Oh, W.K.; Manola, J.; Babcic, V.; Harnam, N.; Kantoff, P.W. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology, 2006, 67(6), 1235-1240.
8. Morant, R.; Bernhard, J.; Dietrich, D.; Gillessen, S.; Bonomo, M.; Borner, M.; Bauer, J.; Cerny, T.; Rochlitz, C.; Wernli, M.; Gschwend, A.; Hanselmann, S.; Hering, F.; Schmid, H.P. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br. J. Cancer, 2004, 90(7), 1312-1317.
9. Morant, R.; Bernhard, J.; Maibach, R.; Borner, M.; Fey, M.F.; Thurlimann, B.; Jacky, E.; Trinkler, F.; Bauer, J.; Zulian, G.; Hanselmann, S.; Hurny, C.; Hering, F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol., 2000, 11(2), 183-188.
10. Morant, R.; Hsu Schmitz, S.F.; Bernhard, J.; Thurlimann, B.; Borner, M.; Wernli, M.; Egli, F.; Forrer, P.; Streit, A.; Jacky, E.; Hanselmann, S.; Bauer, J.; Hering, F.; Schmid, H.P. Vinorelbine in androgen-independent metastatic prostatic carcinoma - a phase II study. Eur. J. Cancer, 2002, 38(12), 1626-1632.
11. Berlin, J.D.; Propert, K.J.; Trump, D.; Wilding, G.; Hudes, G.; Glick, J.; Burch, P.; Keller, A.; Loehrer, P. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am. J. Clin. Oncol., 1998, 21(2), 171-176.
12. Hudes, G.R.; Kosierowski, R.; Greenberg, R.; Ramsey, H.E.; Fox, S.C.; Ozols, R.F.; McAleer, C.A.; Giantonio, B.J. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest. N. Drugs, 1995, 13(3), 235-240.
13. Raghavan, D.; Cox, K.; Pearson, B.S.; Coorey, G.J.; Rogers, J.; Watt, W.H.; Coates, A.S.; McNeil, E.; Grygiel, J.J. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br. J. Urol., 1993, 72(5 Pt 1), 625-628.
14. Saxman, S.; Ansari, R.; Drasga, R.; Miller, M.; Wheeler, B.; McClean, J.; Einhorn, L. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer, 1992, 70(10), 2488-2492.
15. Kelland, L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin. Investig. Drugs, 2007, 16(7), 1009-1021.
16. Rossof, A.H.; Talley, R.W.; Stephens, R.; Thigpen, T.; Samson, M.K.; Groppe, C., Jr.; Eyre, H.J.; Fisher, R. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Cancer Treat. Rep., 1979, 63(9-10), 1557-1564.
17. Moore, M.R.; Troner, M.B.; DeSimone, P.; Birch, R.; Irwin, L. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. Cancer Treat. Rep., 1986, 70(4), 541-542.
18. Merrin, C.E. Treatment of previously untreated (by hormonal manipulation) stage D adenocarcinoma of prostate with combined orchiectomy, estrogen, and cis diamminedichloroplatinum. Urology, 1980, 15(2), 123-126.
19. Qazi, R.; Khandekar, J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol., 1983, 6(2), 203-205.
20. Canobbio, L.; Guarneri, D.; Miglietta, L.; Decensi, A.; Oneto, F.; Boccardo, F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur. J. Cancer, 1993, 29A(15), 2094-2096.
21. Kelly, W.K.; Curley, T.; Slovin, S.; Heller, G.; McCaffrey, J.; Bajorin, D.; Ciolino, A.; Regan, K.; Schwartz, M.; Kantoff, P.; George, D.; Oh, W.; Smith, M.; Kaufman, D.; Small, E.J.; Schwartz, L.; Larson, S.; Tong, W.; Scher, H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol., 2001, 19(1), 44-53.
22. Solit, D.B.; Morris, M.; Slovin, S.; Curley, T.; Schwartz, L.; Larson, S.; Kattan, M.W.; Hartley-Asp, B.; Scher, H.I.; Kelly, W.K. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer, 2003, 98(9), 1842-1848.
23. Ross, R.W.; Beer, T.M.; Jacobus, S.; Bubley, G.J.; Taplin, M.E.; Ryan, C.W.; Huang, J.; Oh, W.K. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer, 2008, 112(3), 521-526.
24. Kelland, L.R. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin. Investig. Drugs, 2000, 9(6), 1373-1382.
25. Sternberg, C.N. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int., 2005, 96(7), 990-994.
26. McKeage, M.J.; Raynaud, F.; Ward, J.; Berry, C.; O'Dell, D.; Kelland, L.R.; Murrer, B.; Santabarabara, P.; Harrap, K.R.; Judson, I.R. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J. Clin. Oncol., 1997, 15(7), 2691-2700.
27. Beale, P.; Raynaud, F.; Hanwell, J.; Berry, C.; Moore, S.; Odell, D.; Judson, I. Phase I study of oral JM216 given twice daily. Cancer. Chemother. Pharmacol., 1998, 42(2), 142-148.
28. Kurata, T.; Tamura, T.; Sasaki, Y.; Fujii, H.; Negoro, S.; Fukuoka, M.; Saijo, N. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine- dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn. J. Clin. Oncol., 2000, 30(9), 377-384.
29. Sessa, C.; Minoia, C.; Ronchi, A.; Zucchetti, M.; Bauer, J.; Borner, M.; de Jong, J.; Pagani, O.; Renard, J.; Weil, C.; D'Incalci, M. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann. Oncol., 1998, 9(12), 1315-1322.
30. Sternberg, C.N.; Whelan, P.; Hetherington, J.; Paluchowska, B.; Slee, P.H.; Vekemans, K.; Van Erps, P.; Theodore, C.; Koriakine, O.; Oliver, T.; Lebwohl, D.; Debois, M.; Zurlo, A.; Collette, L. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 2005, 68(1), 2-9.
31. Sartor, A.O.; Petrylak, D.P.; Witjes, J.A.; Berry, W.R.; Chatta, G.S.; Vaughn, D.J.; Ferrero, J.; Demkow, T.; Eymard, J.C.; Sternberg, C.N. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J. Clin. Oncol. (Meeting Abstracts), 2008, 26(15 Suppl), Abstract 5003.
32. Sternberg, C.N.; Petrylak, D.; Witjes, F.; Ferrero, J.; Eymard, J.; Falcon, S.; Chatta, K.; Vaughn, D.; Berry, W.; Sartor, O. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. J. Clin. Oncol. (Meeting. Abstracts), 2007, 25(18 Suppl), Abstract 5019.
33. Petrylak, D.; Sartor, O.; Witjes, J.; Ferrero, J.; Berry, W.R.; Koletsky, A.; Falcon, S.; Nathan, F.E.; Petrone, M.E.; Sternberg, C. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). ASCO Prostate Cancer Symposium, 2007, Abstract 145.
34. Petrylak, D.P.; Sartor, A.O.; Witjes, J.A.; George, M.; Petrone, M.E.; Noursalehi, M.; McKearn, T.; Calabrò, F.; Sternberg, C.N. Survival benefit in docetaxel-refractory androgen independent prostate cancer (AIPC) patients receiving second-line satraplatin in the SPARC trial. ASCO. Genitourinary Symposium, 2009, Abstract 163.
35. Shah, N.; Dizon, D.S. New-generation platinum agents for solid tumors. Future Oncol., (London, England), 2009, 5(1), 33-42.
36. De Jager, R.L.; Roman, L.; Lopatkin, N.; Karlov, P.; Breitz, H.; Earhart, R. Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC). J. Clin. Oncol., (Meeting Abstracts), 2009, 27(15S), Abstract 5140.
37. Bose, R.N.; Maurmann, L.; Mishur, R.J.; Yasui, L.; Gupta, S.; Grayburn, W.S.; Hofstetter, H.; Salley, T. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc. Natl. Acad. Sci. USA, 2008, 105(47), 18314-18319.
38. Jordan, M.A.; Toso, R.J.; Thrower, D.; Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 1993, 90(20), 9552-9556.
39. McIntosh, J.R.; Grishchuk, E.L.; West, R.R. Chromosome-microtubule interactions during mitosis. Annu. Rev. Cell Dev. Biol., 2002, 18, 193-219.
40. Jordan, M.A.; Margolis, R.L.; Himes, R.H.; Wilson, L. Identification of a distinct class of vinblastine binding sites on microtubules. J. Mol. Biol., 1986, 187(1), 61-73.
41. Himes, R.H. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharma. Ther., 1991, 51(2), 257-267.
42. Ringel, I.; Horwitz, S.B. Studies with RP 56976 (taxotere): a semi-synthetic analogue of taxol. J. Natl. Cancer. Inst., 1991, 83(4), 288-291.
43. Fields-Jones, S.; Koletsky, A.; Wilding, G.; O'Rourke, M.; O'Rourke, T.; Eckardt, J.; Yates, B.; McGuirt, C.; Burris, H.A., 3rd. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann. Oncol., 1999, 10(11), 1307-1310.
44. Soloway, M.S.; deKernion, J.B.; Gibbons, R.P.; Johnson, D.E.; Loening, S.A.; Pontes, J.E.; Prout, G.R., Jr.; Schmidt, J.D.; Scott, W.W.; Chu, T.M.; Gaeta, J.F.; Slack, N.H.; Murphy, G.P. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J. Urol., 1981, 125(5), 664-667.
45. Daliani, D.D.; Assikis, V.; Tu, S.M.; Papandreou, C.N.; Pagliaro, L.C.; Holtkamp, T.; Wang, X.; Thall, P.F.; Logothetis, C.J. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer, 2003, 97(3), 561-567.
46. Abratt, R.P.; Brune, D.; Dimopoulos, M.A.; Kliment, J.; Breza, J.; Selvaggi, F.P.; Beuzeboc, P.; Demkow, T.; Oudard, S. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann. Oncol., 2004, 15(11), 1613-1621.
47. Borden, L.S., Jr.; Clark, P.E.; Lovato, J.; Hall, M.C.; Stindt, D.; Harmon, M.; R, M.M.; Torti, F.M. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer, 2006, 107(5), 1093-1100.
48. Oh, W.K.; Kantoff, P.W. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin. Oncol., 1999, 26(5 Suppl 17), 49-54.
49. Beer, T.M.; Ryan, C.W.; Venner, P.M.; Petrylak, D.P.; Chatta, G.S.; Ruether, J.D.; Redfern, C.H.; Fehrenbacher, L.; Saleh, M.N.; Waterhouse, D.M.; Carducci, M.A.; Vicario, D.; Dreicer, R.; Higano, C.S.; Ahmann, F.R.; Chi, K.N.; Henner, W.D.; Arroyo, A.; Clow, F.W. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol., 2007, 25(6), 669-674.
50. Beer, T.M.; Eilers, K.M.; Garzotto, M.; Egorin, M.J.; Lowe, B.A.; Henner, W.D. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol., 2003, 21(1), 123-128.
51. Press Release: Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar. [cited June 2009]; Available from http://www. fiercebiotech.com/press- releases/press-release-novacea-halts-late-stage-trial-prostate-cancer-drug- asentar
52. Chan, J.S.; Beer, T.M.; Quinn, D.I.; Pinski, J.K.; Garzotto, M.; Sokoloff, M.; Dehaze, D.R.; Ryan, C.W. A phase II study of highdose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int., 2008, 102(11), 1601-1606.
53. Ferrero, J.M.; Chamorey, E.; Oudard, S.; Dides, S.; Lesbats, G.; Cavaglione, G.; Nouyrigat, P.; Foa, C.; Kaphan, R. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer, 2006, 107(4), 738-745.
54. Bollag, D.M.; McQueney, P.A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C.M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 1995, 55(11), 2325-2333.
55. Gerth, K.; Bedorf, N.; Hofle, G.; Irschik, H.; Reichenbach, H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot., 1996, 49(6), 560-563.
56. Lee, F.Y.; Borzilleri, R.; Fairchild, C.R.; Kim, S.H.; Long, B.H.; Reventos-Suarez, C.; Vite, G.D.; Rose, W.C.; Kramer, R.A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res., 2001, 7(5), 1429-1437.
57. Lee, J.J.; Kelly, W.K. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat. Clin. Pract., 2009, 6(2), 85-92.
58. Bhandari, M.S.; Hussain, M. Epothilones and the next generation of phase III trials for prostate cancer. BJU Int., 2005, 96(3), 296-302.
59. Goodin, S.; Kane, M.P.; Rubin, E.H. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol., 2004, 22(10), 2015-2025.
60. Hussain, M.; Tangen, C.M.; Lara, P.N., Jr.; Vaishampayan, U.N.; Petrylak, D.P.; Colevas, A.D.; Sakr, W.A.; Crawford, E.D. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol., 2005, 23(34), 8724-8729.
61. Galsky, M.D.; Small, E.J.; Oh, W.K.; Chen, I.; Smith, D.C.; Colevas, A.D.; Martone, L.; Curley, T.; Delacruz, A.; Scher, H.I.; Kelly, W.K. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J. Clin. Oncol., 2005, 23(7), 1439-1446.
62. Rosenberg, J.E.; Weinberg, V.K.; Kelly, W.K.; Michaelson, D.; Hussain, M.H.; Wilding, G.; Gross, M.; Hutcheon, D.; Small, E.J. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer, 2007, 110(3), 556-563.
63. Rosenberg, J.E.; Ryan, C.J.; Weinberg, V.K.; Smith, D.C.; Hussain, M.; Beer, T.M.; Ryan, C.W.; Mathew, P.; Pagliaro, L.C.; Harzstark, A.L.; Sharib, J.; Small, E.J. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J. Clin. Oncol., 2009, 27(17), 2772-2778.
64. Beardsley, E.K.; Saad, F.; Eigl, B.; Venner, P.; Hotte, S.; Winquist, E.; Ko, Y.J.; Sridhar, S.S.; Chi, K.N. A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel. J. Clin. Oncol. (Meeting Abstracts), 2009, 27(15S), Abstract 5139.
65. Mita, A.C.; Denis, L.J.; Rowinsky, E.K.; Debono, J.S.; Goetz, A.D.; Ochoa, L.; Forouzesh, B.; Beeram, M.; Patnaik, A.; Molpus, K.; Semiond, D.; Besenval, M.; Tolcher, A.W. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res., 2009, 15(2), 723-730.
66. XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC). [cited July 2009]; Available from http://clinicaltrials.gov/ct2/show/NCT00417079.
67. Jordan, M.A.; Kamath, K.; Manna, T.; Okouneva, T.; Miller, H.P.; Davis, C.; Littlefield, B.A.; Wilson, L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther., 2005, 4(7), 1086-1095.
68. Towle, M.J.; Salvato, K.A.; Budrow, J.; Wels, B.F.; Kuznetsov, G.; Aalfs, K.K.; Welsh, S.; Zheng, W.; Seletsk, B.M.; Palme, M.H.; Habgood, G.J.; Singer, L.A.; Dipietro, L.V.; Wang, Y.; Chen, J.J.; Quincy, D.A.; Davis, A.; Yoshimatsu, K.; Kishi, Y.; Yu, M.J.; Littlefield, B.A. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res., 2001, 61(3), 1013-1021.
69. NCT00337077. E7389 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy. [cited June 2009]; Available from http://clinicaltrials.gov/ct2/show/NCT00337077?term=ECOG+5805&rank=1.
70. de Bono, J.S.; Maroto, P.; Calvo, E.; Sonpavde, G.; Cartwright, T.H.; Loesch, D.; Feit, K.; Zang, E.A.; Wanders, J.; Petrylak, D.P. Phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. ASCO Genitourinary Symposium, 2009, Abstract 166.
71. Davis, D.A.; Sarkar, S.H.; Hussain, M.; Li, Y.; Sarkar, F.H. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer, 2006, 6, 22.
72. Beer, T.M.; Goldman, B.; Synold, T.W.; Ryan, C.W.; Vasist, L.S.; Van Veldhuizen, P.J., Jr.; Dakhil, S.R.; Lara, P.N., Jr.; Drelichman, A.; Hussain, M.H.; Crawford, E.D. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin. Genitour. Cancer, 2008, 6(2), 103-109.
73. Febbo, P.G.; Richie, J.P.; George, D.J.; Loda, M.; Manola, J.; Shankar, S.; Barnes, A.S.; Tempany, C.; Catalona, W.; Kantoff, P.W.; Oh, W.K. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res., 2005, 11(14), 5233-5240.
74. Oh, W.K.; George, D.J.; Kaufman, D.S.; Moss, K.; Smith, M.R.; Richie, J.P.; Kantoff, P.W. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin. Oncol., 2001, 28(4 Suppl. 15), 40-44.
75. Hussain, M.; Smith, D.C.; El-Rayes, B.F.; Du, W.; Vaishampayan, U.; Fontana, J.; Sakr, W.; Wood, D. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology, 2003, 61(4), 774-780.
76. Eastham, J.A.; Kelly, W.K.; Grossfeld, G.D.; Small, E.J. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology., 2003, 62(Suppl 1), 55-62.
77. Dreicer, R.; Magi-Galluzzi, C.; Zhou, M.; Rothaermel, J.; Reuther, A.; Ulchaker, J.; Zippe, C.; Fergany, A.; Klein, E.A. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology, 2004, 63(6), 1138-1142.
78. Garzotto, M.; Myrthue, A.; Higano, C.S.; Beer, T.M. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol. Oncol., 2006, 24(3), 254-259.
79. Friedman, J.; Dunn, R.L.; Wood, D.; Vaishampayan, U.; Wu, A.; Bradley, D.; Montie, J.; Sarkar, F.H.; Shah, R.B.; Hussain, M. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J. Urol., 2008, 179(3), 911-915; discussion 915-916.